Observational studyFrontiers in immunology2026
Comparative efficacy of ripertamab, rituximab, and efgartigimod in chronic inflammatory demyelinating polyneuropathy: an exploratory real-world multicenter cohort study.
Observational study in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To analyze and compare the efficacy of ripertamab, rituximab, and efgartigimod in patients with chronic inflammatory demyelinating polyneuropathy (CIDP), focusing on treatment response rates, relapse rates, drug safety, long-term clinical outcomes, and biomarker characteristics. Methods: A multicenter, retrospective cohort study was conducted, patients diagnosed with CIDP were enrolled if they had received at least one course of ripertamab, rituximab, or efgartigimod. A total of 60 patients were included. At baseline and at each follow-up time point, the clinical results were evaluated by disease-specific grading scale, and the correlations between biomarker spectrum and disease activity was explored. Results: A total of 60 patients were enrolled, with 27, 19, and 14 patients assigned to the rituximab, ripertamab, and efgartigimod groups, At the 3-month post-treatment assessment, the mean of the INCAT score decreased by 0.519 points in the rituximab group, 1.737 points in the ripertamab group, and 0.214 points in the efgartigimod group as compared to baseline. Conclusion: Ripertamab demonstrated efficacy in managing short-term disease outcomes in patients with CIDP, with no significant difference observed when compared to rituximab or efgartigimod. These findings suggest that ripertamab may represent a potential therapeutic strategy for CIDP in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.